Thank you for Subscribing to CIO Applications Weekly Brief

FOLDAX Acquires New Polymer Technology Patent
"While we believe LifePolymer is ideal for heart valves, we are also excited about the possibility of its application to other medical devices," said Gregory D. Casciaro, Foldax CEO.
By
CIO Applications | Friday, June 02, 2023

Foldax reveals the ownership of CSIRO's polymer technology patent and has incorporated the polymer technology into its LifePolymer materials platform.
FREMONT, CA: "While we believe LifePolymer is ideal for heart valves, we are also excited about the possibility of its application to other medical devices," said Gregory D. Casciaro, Foldax CEO. "The biocompatible and durable material properties of LifePolymer may make it potentially ideal for drug delivery, orthopedics, glucose monitoring, cardiac cannula, blood pumps, blood oxygenation circuits, vascular, stent coverings, electrophysiology, and non-medical coatings."
Foldax reveals its agreement with Australia's CSIRO to fully integrate a polymer technology patent family. Based on testing conducted by Foldax, it has indicated that the polymer technology is compatible with blood, has low protein adhesion, and cannot cling to proteins, cells, or calcium. Due to its high biocompatibility and durability, LifePolymer may be a great medical device material.
Stay ahead of the industry with exclusive feature stories on the top companies, expert insights and the latest news delivered straight to your inbox. Subscribe today.
The TRIA„ heart valves in Foldax's portfolio are the first to use the patented LifePolymer material. These valves combine the polymer material with a leaflet designed to prevent calcification, withstand stresses and strains without failure, and restore patient quality of life without requiring lifelong anticoagulant medication.
In Foldax's regulatory submissions to the FDA, the LifePolymer technology has undergone thorough biological safety testing. The TRIA biopolymer heart valve is the first polymer valve to ever get FDA approval for human research in both the aortic and mitral positions.
The TRIA valve is the first and only heart valve produced robotically, minimizing variability and enabling high accuracy, repeatability, and quality while significantly enhancing production costs. LifePolymer characteristics enable this. Other medical devices made from LifePolymer may be produced via robotic manufacturing, resulting in a strong supply chain and much cheaper manufacturing costs. This would significantly increase patient access to potentially life-changing medicines.
More in News

